Many approaches have achieved encouraging outcomes in preclinical and early clinical stages, like immune checkpoint inhibitors (ICIs), including antibodies against PD-1, its ligand PD-L1, CTLA-4, and CAR T cell therapy, failed to exert their therapeutic effects in glioma [10]. The gene discussed is CD274; the disease is glioma.